BRD4 and neoplasm: One promising strategy involves the use of bromodomain-containing protein 4 (BRD4) inhibitors or bromodomain and extraterminal domain inhibitors (BETis) to downregulate NFIC expression, potentially inhibiting tumor progression and increasing the efficacy of existing treatments [108].